Clinical Laboratory, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, 313000, China.
Department of Respiration, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, 313000, China.
Immunotherapy. 2022 Aug;14(12):945-956. doi: 10.2217/imt-2021-0238. Epub 2022 Jul 13.
Previously published data was collected and a meta-analysis was conducted to precisely identify the prognostic and clinicopathological significance of soluble programmed cell death ligand-1 (sPD-L1) in patients with non-small-cell lung cancer (NSCLC). Combined hazard ratios (HRs), odds ratios and 95% confidence intervals were used to assess the correlation between sPD-L1 expression and prognosis in patients with NSCLC. A total of 11 studies with 976 patients were included in this meta-analysis. High levels of sPD-L1 were associated with poor overall and progression-free survival (HR: 2.65, 95% CI: 2.32-3.02; p < 0.001 vs HR: 2.02, 95% CI: 1.24-3.29; p = 0.005). sPD-L1 level was not significantly correlated with sex, smoking status, age, Eastern Cooperative Oncology Group performance status, subtype or EGFR mutation. High levels of sPD-L1 are a prognostic marker for poor survival in patients with NSCLC.
先前发表的数据被收集并进行了荟萃分析，以准确确定可溶性程序性死亡配体-1（sPD-L1）在非小细胞肺癌（NSCLC）患者中的预后和临床病理意义。采用合并危险比（HR）、优势比和 95%置信区间来评估 sPD-L1 表达与 NSCLC 患者预后之间的相关性。共有 11 项研究，涉及 976 名患者，被纳入本荟萃分析。sPD-L1 高水平与总生存期和无进展生存期不良相关（HR：2.65，95%CI：2.32-3.02；p<0.001 vs HR：2.02，95%CI：1.24-3.29；p=0.005）。sPD-L1 水平与性别、吸烟状态、年龄、东部合作肿瘤学组表现状态、亚型或 EGFR 突变无显著相关性。sPD-L1 高水平是 NSCLC 患者生存不良的预后标志物。
